Richard Katzman

Senior Associate, Stockholm

Corporate Advisory, Equity Capital Markets, Public M&A

Contact

Richard Katzman is a Stockholm-based Senior Associate working with Roschier’s Public M&A, Corporate Advisory and Equity Capital Markets practices. He joined Roschier in 2019.

Richard is current on a leave of absence.

Work highlights

Richard Katzman’s experience includes advising:

  • Navamedic in the recommended cash offer to acquire Sensidose;
  • KKR’s life science platform Gamma Biosciences in the USD 215 million sale of Astrea Bioseparations to Biotage;
  • Aareon AG in its acquisition and delisting of Momentum Software Group;
  • Cibus Nordic Real Estate in connection with a directed share issue through an accelerated book-building procedure;
  • Cibus Nordic Real Estate in its acquisition of a Finnish real estate portfolio and directed share issue to AB Sagax;
  • Cibus Nordic Real Estate in connection with a directed share issue through an accelerated book-building procedure;
  • Synsam and CVC in the IPO and listing of Synsam’s shares on Nasdaq Stockholm;
  • Castellum in the SEK 26.9 billion public offer for Kungsleden;
  • Cibus Nordic Real Estate in connection with a directed share issue through an accelerated book-building procedure;
  • EQT IX and Roar BidCo in their SEK 23.6 billion public offer for Recipharm;
  • Danske Bank, Handelsbanken and Nordea in the fully guaranteed SEK 1.7 billion rights issue in Gränges AB;
  • Cibus Nordic Real Estate AB (publ) in the SEK 1.9 billion acquisition of 111 properties from Coop and SEK 0.9 billion accelerated book building;
  • Filtronic PLC (listed on AIM operated by the London Stock Exchange) in the sale of its telecoms antenna business to Microdata Telecom Innovation;
  • Searchlight Capital Partners in the acquisition of shares to obtain more than 90% ownership of Opus Group.
Career

Roschier (2019-)

Memberships

Member of the Swedish Bar Association

Education

Uppsala University, LL.M. (2019)

Languages

English, Swedish